Patients with renal cell carcinoma with clinical stage T1a (maximum tumor diameter =4cm and confined to the kidney)
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. The patient voluntarily agreed to join the clinical study, signed the informed consent form voluntarily, and agreed to participate in all preoperative and postoperative visits, examinations and surgical treatment according to the requirements of the research program (the informed consent form needs to be approved by the ethics committee of the hospital, and the informed consent of the patient is obtained before surgery). 2. Age 18-75 years old, gender unlimited. 3. Participants met clinical staging criteria for renal cancer in the T3 period or renal hamartoma with tumor diameter >=4cm and feasible robot-assisted laparoscopic partial nephrectomy;
Exclusion criteria
Exclusion criteria: 1. Previously poorly controlled diabetes mellitus (fingertip fasting blood glucose >7.8mmol/L, fingertip postprandial blood glucose >10mmol/L, venous hemoglobin A1c >7% were detected in our hospital before and after admission); 2. In the past 1 month, he has undergone other operations related to the kidney (such as percutaneous nephrolithotomy, ureteroscopic lithotripsy, extracorporeal shock wave lithotripsy, pyeloureteroplasty, etc.), transurethral plasma resection of the prostate, urine rerouting, etc., which may affect kidney function; 3. Severe heart, brain, liver, kidney and other organ dysfunction; 4. Patients with severe immune deficiency or severe psychiatric disorders or renal cancer with distant metastases (e.g., lung metastasis, bone metastasis); 5. Severe malnutrition, pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| total renal GFR(ml/min);affected renal GFR(ml/min); | — |
Secondary
| Measure | Time frame |
|---|---|
| Creatinine;urea nitrogen;leakage of urine; | — |
Countries
China
Contacts
Peking University Shenzhen Hospital